DMPA-SC stock: Cross-site trends by facility type

doi:10.1016/j.conx.2022.100075

. 2022 Apr 8:4:100075.

doi: 10.1016/j.conx.2022.100075. eCollection 2022.

DMPA-SC stock: Cross-site trends by facility type

Sophia Magalona¹, Shannon N Wood¹, Frederick Makumbi², Funmilola M OlaOlorun³, Elizabeth Omoluabi⁴, Akilimali Z Pierre⁵, Georges Guiella⁶, Jane Cover⁷, Philip Anglewicz¹

Affiliations

¹ Department of Population Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
² Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.
³ Department of Community Medicine, University of Ibadan, Ibadan, Nigeria.
⁴ Statistics and Population Studies Department, University of the Western Cape, Bellville, South Africa.
⁵ Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo.
⁶ Institut Supérieur des Sciences de la Population (ISSP/University of Ouagadougou), Ouagadougou, Burkina Faso.
⁷ PATH, Seattle, WA, USA.

PMID: 35493973
PMCID: PMC9046645
DOI: 10.1016/j.conx.2022.100075

DMPA-SC stock: Cross-site trends by facility type

Sophia Magalona et al. Contracept X. 2022.

. 2022 Apr 8:4:100075.

doi: 10.1016/j.conx.2022.100075. eCollection 2022.

Authors

Sophia Magalona¹, Shannon N Wood¹, Frederick Makumbi², Funmilola M OlaOlorun³, Elizabeth Omoluabi⁴, Akilimali Z Pierre⁵, Georges Guiella⁶, Jane Cover⁷, Philip Anglewicz¹

Affiliations

¹ Department of Population Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
² Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.
³ Department of Community Medicine, University of Ibadan, Ibadan, Nigeria.
⁴ Statistics and Population Studies Department, University of the Western Cape, Bellville, South Africa.
⁵ Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo.
⁶ Institut Supérieur des Sciences de la Population (ISSP/University of Ouagadougou), Ouagadougou, Burkina Faso.
⁷ PATH, Seattle, WA, USA.

PMID: 35493973
PMCID: PMC9046645
DOI: 10.1016/j.conx.2022.100075

Abstract

Objectives: To measure trends in the supply of DMPA-SC in public and private health facilities and compare with other prominent modern methods.

Study design: We used repeated cross-sectional data from service-delivery-point surveys in six settings: Burkina Faso, Democratic Republic of Congo (Kinshasa and Kongo Central), Nigeria (Kano and Lagos), and Uganda, each with 3-5 rounds of data collected between 2016 and 2020. We analyzed trends in DMPA-SC availability using percent of service delivery points offering the method and percent experiencing stockouts; trends were compared with those for DMPA-IM, IUD, implants, and other short-acting methods, by facility type.

Results: All settings showed increased offering of DMPA-SC over time for both private and public facilities. Larger proportions of public facilities provided DMPA-SC compared to private facilities (66%-97% vs 16%-50% by 2019-2020). DMPA-SC was provided by fewer facilities than DMPA-IM (90%-100% public, 34%-69% private by 2019-2020), but comparable to implants (83%-100% public, 15%-52% private by 2019-2020) and IUDs (55%-91% public, 0%-44% private by 2019-2020). Trends of DMPA-SC stock varied by setting, with more consistent stock available in private facilities in the DRC and in public facilities in Burkina Faso and Nigeria. Uganda showed decreasing stock in public facilities but increasing stock in private facilities.

Conclusion: DMPA-SC availability has been increasing since its introduction in sub-Saharan Africa, yet significant gaps in stock exist. Countries should consider alternative distribution models to address these issues.

Implications: Our findings may help inform countries about the need to monitor DMPA-SC availability and to consider solutions that ensure contraceptive options are available to women who need them and disruptions to contraceptive use are minimized.

Keywords: DMPA-SC; Family planning; Reproductive health; Sayana press; Sub-Saharan Africa; Supply chain.

PubMed Disclaimer

Figures

Fig 1 — **Fig. 1**
Percentage of service delivery points that provide DMPA-SC and other modern methods by facility.

Fig 2 — **Fig. 2**
DMPA-SC stock status in public and private service delivery points.

See this image and copyright information in PMC

Cited by

A longitudinal study examining how self-injection social norms are associated with contraceptive self-injectable interest and use in rural Uganda.
Sedlander E, Turaga N, Birabwa C, Wasswa R, Phillips B, Amongin D, Challa S, Nano S, Kyobe B, Kayego A, Waiswa P, Holt K. Sedlander E, et al. BMC Womens Health. 2025 Jun 30;25(Suppl 1):288. doi: 10.1186/s12905-025-03878-x. BMC Womens Health. 2025. PMID: 40588728 Free PMC article.
Determinants of DMPA-SC self-care/self-injectable contraceptive uptake among modern contraceptive users in Burkina Faso: findings from the 2021 demographic and health survey.
Bado AR. Bado AR. Front Glob Womens Health. 2024 Sep 5;5:1385446. doi: 10.3389/fgwh.2024.1385446. eCollection 2024. Front Glob Womens Health. 2024. PMID: 39301506 Free PMC article.
Self-injected contraceptives: does the investment reflect women's preferences?
Wood SN, Magalona S, Zimmerman LA, OlaOlorun F, Omoluabi E, Akilimali P, Guiella G, Gichangi P, Anglewicz P. Wood SN, et al. BMJ Glob Health. 2022 Jul;7(7):e008862. doi: 10.1136/bmjgh-2022-008862. BMJ Glob Health. 2022. PMID: 35835480 Free PMC article. Review.

References

1. Cole K, Saad A. The coming-of-age of subcutaneous injectable contraception. Glob Health Sci Pract. 2018;6:1–5. doi: 10.9745/GHSP-D-18-00050. - DOI - PMC - PubMed
1. Burke HM, Mueller MP, Perry B, Packer C, Bufumbo L, Mbengue D, et al. Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal. Contraception. 2014;89:361–367. doi: 10.1016/j.contraception.2014.01.022. - DOI - PubMed
1. Anglewicz P, Akilimali P, Guiella G, Kayembe P, Kibira SPS, Makumbi F, et al. Trends in subcutaneous depot medroxyprogesterone acetate (DMPA-SC) use in Burkina Faso, the Democratic Republic of Congo and Uganda. Contracept X. 2019;1 doi: 10.1016/j.conx.2019.100013. - DOI - PMC - PubMed
1. DMPA-SC Access Collaborative Project . PATH & John Snow, Inc.; Seattle, Washington and Arlington, VA: 2022. Status Update: Global Progress with DMPA-SC and Self-injection Scale Up Quarterly Monitoring Report | Q4 2021.
1. Anglewicz P, Larson E, Akilimali P, Guiella G, Kayembe P, Kibira SPS, et al. Characteristics associated with use of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Burkina Faso, Democratic Republic of Congo, and Uganda. Contracept X. 2021;3 doi: 10.1016/j.conx.2021.100055. - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources

[1] Cole K, Saad A. The coming-of-age of subcutaneous injectable contraception. Glob Health Sci Pract. 2018;6:1–5. doi: 10.9745/GHSP-D-18-00050. - DOI - PMC - PubMed

[2] Cole K, Saad A. The coming-of-age of subcutaneous injectable contraception. Glob Health Sci Pract. 2018;6:1–5. doi: 10.9745/GHSP-D-18-00050. - DOI - PMC - PubMed

[3] Burke HM, Mueller MP, Perry B, Packer C, Bufumbo L, Mbengue D, et al. Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal. Contraception. 2014;89:361–367. doi: 10.1016/j.contraception.2014.01.022. - DOI - PubMed

[4] Burke HM, Mueller MP, Perry B, Packer C, Bufumbo L, Mbengue D, et al. Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal. Contraception. 2014;89:361–367. doi: 10.1016/j.contraception.2014.01.022. - DOI - PubMed

[5] Anglewicz P, Akilimali P, Guiella G, Kayembe P, Kibira SPS, Makumbi F, et al. Trends in subcutaneous depot medroxyprogesterone acetate (DMPA-SC) use in Burkina Faso, the Democratic Republic of Congo and Uganda. Contracept X. 2019;1 doi: 10.1016/j.conx.2019.100013. - DOI - PMC - PubMed

[6] Anglewicz P, Akilimali P, Guiella G, Kayembe P, Kibira SPS, Makumbi F, et al. Trends in subcutaneous depot medroxyprogesterone acetate (DMPA-SC) use in Burkina Faso, the Democratic Republic of Congo and Uganda. Contracept X. 2019;1 doi: 10.1016/j.conx.2019.100013. - DOI - PMC - PubMed

[7] DMPA-SC Access Collaborative Project . PATH & John Snow, Inc.; Seattle, Washington and Arlington, VA: 2022. Status Update: Global Progress with DMPA-SC and Self-injection Scale Up Quarterly Monitoring Report | Q4 2021.

[8] DMPA-SC Access Collaborative Project . PATH & John Snow, Inc.; Seattle, Washington and Arlington, VA: 2022. Status Update: Global Progress with DMPA-SC and Self-injection Scale Up Quarterly Monitoring Report | Q4 2021.

[9] Anglewicz P, Larson E, Akilimali P, Guiella G, Kayembe P, Kibira SPS, et al. Characteristics associated with use of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Burkina Faso, Democratic Republic of Congo, and Uganda. Contracept X. 2021;3 doi: 10.1016/j.conx.2021.100055. - DOI - PMC - PubMed

[10] Anglewicz P, Larson E, Akilimali P, Guiella G, Kayembe P, Kibira SPS, et al. Characteristics associated with use of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Burkina Faso, Democratic Republic of Congo, and Uganda. Contracept X. 2021;3 doi: 10.1016/j.conx.2021.100055. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

DMPA-SC stock: Cross-site trends by facility type

Affiliations

DMPA-SC stock: Cross-site trends by facility type

Authors

Affiliations

Abstract

Figures

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources